Mavacoxib
Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.[1] It acts as a COX-2 inhibitor.[2]
 | |
| Clinical data | |
|---|---|
| Trade names | Trocoxil |
| AHFS/Drugs.com | International Drug Names |
| ATCvet code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.248.948  |
| Chemical and physical data | |
| Formula | C16H11F4N3O2S |
| Molar mass | 385.34 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mavacoxib, along with other COX-2 selective inhibitors, celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[3][4]
References
- European Public Assessment Report (EPAR): Trocoxil, European Medicines Agency
- Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.
- Langreth R (June 23, 2003). "The Chemical Cobbler". Forbes.
- "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. St. Louis Section, American Chemical Society. 52 (5): 2. May 2001. Archived from the original (PDF) on 15 April 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.